@misc{10481/75980,
year = {2022},
month = {5},
url = {http://hdl.handle.net/10481/75980},
abstract = {Alzheimer’s disease (AD) is an age-dependent, progressive disorder affecting millions of
people. Currently, the therapeutics for AD only treat the symptoms. Although they have been used
to discover new products of interest for this disease, mammalian models used to investigate the
molecular determinants of this disease are often prohibitively expensive, time-consuming and very
complex. On the other hand, cell cultures lack the organism complexity involved in AD. Given the
highly conserved neurological pathways between mammals and invertebrates, Caenorhabditis elegans
has emerged as a powerful tool for the investigation of the pathophysiology of human AD. Numerous
models of both Tau- and A -induced toxicity, the two prime components observed to correlate with
AD pathology and the ease of performing RNA interference for any gene in the C. elegans genome,
allow for the identification of multiple therapeutic targets. The effects of many natural products in
main AD hallmarks using these models suggest promising health-promoting effects. However, the
way in which they exert such effects is not entirely clear. One of the reasons is that various possible
therapeutic targets have not been evaluated in many studies. The present review aims to explore
shared therapeutical targets and the potential of each of them for AD treatment or prevention.},
publisher = {MDPI},
keywords = {Neurodegenerative disease},
keywords = {Beta-amyloid},
keywords = {Tau protein},
keywords = {Nutraceutical},
keywords = {Food},
title = {Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic Models},
doi = {10.3390/diseases10020028},
author = {Navarro Hortal, María Dolores and Romero Márquez, José Manuel and Osta, Safa and Jiménez Trigo, Victoria and Muñoz Ollero, Pedro and Varela López, Alfonso},
}